Mitsunori Seki

Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial

Atsushi Nakajima, Mitsunori Seki, Shinya Taniguchi et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 162 citations

Urology, Functional Gastrointestinal Disorder, Gastrointestinal Pharmacology +3

Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial

Atsushi Nakajima, Mitsunori Seki, Shinya Taniguchi · Journal of Gastroenterology · 2017 · 61 citations · Full text

Direct Inhibition of Pituitary LH Secretion in Rats by CB-154 (2-Br-β-ergocryptine)

Mitsunori Seki, Katsuyoshi Seki, Terufumi Yoshihara et al. · Endocrinology · 1974 · 24 citations

Human Growth, Comparative Endocrinology, Lh Release +22

SUCCESSFUL OVULATION AND PREGNANCY ACHIEVED BY CB-154 (2-Br-α-ergocryptine) IN A WOMAN WITH CHIARI-FROMMEL SYNDROME¹

Katsuyoshi Seki, Mitsunori Seki · The Journal of Clinical Endocrinology & Metabolism · 1974 · 20 citations

Infertility, Fertility, Female Infertility +14

SERUM FSH RISE INDUCED BY CB-154 (2-Br-α-ergocryptine) IN POSTPARTUM WOMEN

Katsuyoshi Seki, Mitsunori Seki, Toshiko Okumura · The Journal of Clinical Endocrinology & Metabolism · 1974 · 15 citations

Serum Fsh Levels, Reproductive Health, Gynecology +17